Ovarian germ cell malignancies

The Yale University experience

Peter E. Schwartz, Setsuko K Chambers, Joseph T. Chambers, Ernest Kohorn, Sue McIntosh

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Eighty-one patients with ovarian germ cell malignancies (immature teratoma 29, dysgerminoma 26, endodermal sinus tumors 15, mixed germ cell tumor 8, other 3) seen or consulted on at Yale University over a 15 year period are presented. Initial therapy was successful in 70 of 81 (86.4%) patients and 75 (92.6%) are currently alive and disease free. Early stage dysgerminomas may be safely treated with surgery whereas advanced disease is exquisitely sensitive to vincristine, actinomycin D, and cyclophosphamide (VAC) therapy. Early stage immature teratoma is uniformly successfully treated with short-term VAC whereas advanced disease requires longer treatment. Early stage endodermal sinus tumor (EST) and mixed germ cell tumors may be effectively treated with VAC or platinum-based therapy but advanced disease should be treated with paltinum-based regimens. Serial alpha fetoprotein assays should determine duration of therapy in tumors containing EST elements. Conservative surgery to preserve reproductive function is appropriate for all patients with early stage ovarian germ cell malignancies and selected patients with advanced disease.

Original languageEnglish (US)
Pages (from-to)26-31
Number of pages6
JournalGynecologic Oncology
Volume45
Issue number1
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Germ Cells
Endodermal Sinus Tumor
Dactinomycin
Vincristine
Dysgerminoma
Cyclophosphamide
Germ Cell and Embryonal Neoplasms
Teratoma
Neoplasms
Therapeutics
alpha-Fetoproteins
Platinum

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Ovarian germ cell malignancies : The Yale University experience. / Schwartz, Peter E.; Chambers, Setsuko K; Chambers, Joseph T.; Kohorn, Ernest; McIntosh, Sue.

In: Gynecologic Oncology, Vol. 45, No. 1, 1992, p. 26-31.

Research output: Contribution to journalArticle

Schwartz, Peter E. ; Chambers, Setsuko K ; Chambers, Joseph T. ; Kohorn, Ernest ; McIntosh, Sue. / Ovarian germ cell malignancies : The Yale University experience. In: Gynecologic Oncology. 1992 ; Vol. 45, No. 1. pp. 26-31.
@article{ff116b56e556429aa949d8133eb31d37,
title = "Ovarian germ cell malignancies: The Yale University experience",
abstract = "Eighty-one patients with ovarian germ cell malignancies (immature teratoma 29, dysgerminoma 26, endodermal sinus tumors 15, mixed germ cell tumor 8, other 3) seen or consulted on at Yale University over a 15 year period are presented. Initial therapy was successful in 70 of 81 (86.4{\%}) patients and 75 (92.6{\%}) are currently alive and disease free. Early stage dysgerminomas may be safely treated with surgery whereas advanced disease is exquisitely sensitive to vincristine, actinomycin D, and cyclophosphamide (VAC) therapy. Early stage immature teratoma is uniformly successfully treated with short-term VAC whereas advanced disease requires longer treatment. Early stage endodermal sinus tumor (EST) and mixed germ cell tumors may be effectively treated with VAC or platinum-based therapy but advanced disease should be treated with paltinum-based regimens. Serial alpha fetoprotein assays should determine duration of therapy in tumors containing EST elements. Conservative surgery to preserve reproductive function is appropriate for all patients with early stage ovarian germ cell malignancies and selected patients with advanced disease.",
author = "Schwartz, {Peter E.} and Chambers, {Setsuko K} and Chambers, {Joseph T.} and Ernest Kohorn and Sue McIntosh",
year = "1992",
doi = "10.1016/0090-8258(92)90486-3",
language = "English (US)",
volume = "45",
pages = "26--31",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Ovarian germ cell malignancies

T2 - The Yale University experience

AU - Schwartz, Peter E.

AU - Chambers, Setsuko K

AU - Chambers, Joseph T.

AU - Kohorn, Ernest

AU - McIntosh, Sue

PY - 1992

Y1 - 1992

N2 - Eighty-one patients with ovarian germ cell malignancies (immature teratoma 29, dysgerminoma 26, endodermal sinus tumors 15, mixed germ cell tumor 8, other 3) seen or consulted on at Yale University over a 15 year period are presented. Initial therapy was successful in 70 of 81 (86.4%) patients and 75 (92.6%) are currently alive and disease free. Early stage dysgerminomas may be safely treated with surgery whereas advanced disease is exquisitely sensitive to vincristine, actinomycin D, and cyclophosphamide (VAC) therapy. Early stage immature teratoma is uniformly successfully treated with short-term VAC whereas advanced disease requires longer treatment. Early stage endodermal sinus tumor (EST) and mixed germ cell tumors may be effectively treated with VAC or platinum-based therapy but advanced disease should be treated with paltinum-based regimens. Serial alpha fetoprotein assays should determine duration of therapy in tumors containing EST elements. Conservative surgery to preserve reproductive function is appropriate for all patients with early stage ovarian germ cell malignancies and selected patients with advanced disease.

AB - Eighty-one patients with ovarian germ cell malignancies (immature teratoma 29, dysgerminoma 26, endodermal sinus tumors 15, mixed germ cell tumor 8, other 3) seen or consulted on at Yale University over a 15 year period are presented. Initial therapy was successful in 70 of 81 (86.4%) patients and 75 (92.6%) are currently alive and disease free. Early stage dysgerminomas may be safely treated with surgery whereas advanced disease is exquisitely sensitive to vincristine, actinomycin D, and cyclophosphamide (VAC) therapy. Early stage immature teratoma is uniformly successfully treated with short-term VAC whereas advanced disease requires longer treatment. Early stage endodermal sinus tumor (EST) and mixed germ cell tumors may be effectively treated with VAC or platinum-based therapy but advanced disease should be treated with paltinum-based regimens. Serial alpha fetoprotein assays should determine duration of therapy in tumors containing EST elements. Conservative surgery to preserve reproductive function is appropriate for all patients with early stage ovarian germ cell malignancies and selected patients with advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=0026773297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026773297&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(92)90486-3

DO - 10.1016/0090-8258(92)90486-3

M3 - Article

VL - 45

SP - 26

EP - 31

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -